How AAV gene therapies enter cells
Adeno-Associated Virus Gene Therapy Vectors: Molecular Interactions on Cell Entry
This research looks at how AAV gene therapy viruses get into cells so treatments for genetic diseases like Duchenne muscular dystrophy can work better and safer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-11171619 on NIH RePORTER |
What this research studies
From a patient's point of view, this work aims to find exactly how AAV gene therapy particles attach to and enter human cells by studying the host proteins that act as receptors. Researchers will make 3D pictures of whole virus-receptor complexes using cryo-electron tomography and high-resolution cryo-electron microscopy of the receptor parts, and they will map how the virus changes shape to release an enzyme needed to escape endosomes. They will also study antibodies that block AAV to understand immune interference, with the goal of guiding safer, more efficient gene therapies.
Who could benefit from this research
Good fit: People with genetic diseases that are candidates for AAV-based gene therapy (for example Duchenne muscular dystrophy or other inherited disorders) would be the main future beneficiaries and possible future trial candidates.
Not a fit: Patients whose conditions are not targeted by AAV approaches or who are not eligible for gene therapy would be unlikely to see direct benefit from this basic lab research.
Why it matters
Potential benefit: If successful, this could allow lower doses and fewer immune side effects, making AAV gene therapies safer and more effective for patients with inherited conditions.
How similar studies have performed: AAV gene therapies have succeeded in some diseases (for example spinal muscular atrophy and certain retinal dystrophies), but this molecular-entry and high-resolution imaging work is a more basic and relatively novel approach focused on improving vector performance and safety.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Chapman, Michael S. — University of Missouri-Columbia
- Study coordinator: Chapman, Michael S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.